Literature DB >> 33407591

Extracellular vesicle-encapsulated microRNA-424 exerts inhibitory function in ovarian cancer by targeting MYB.

Ping Li1, Hongyan Xin2, Lili Lu3.   

Abstract

BACKGROUND: Recent studies have suggested a crucial role of mesenchymal stem cell (MSC)-derived extracellular vesicles (EVs) in ovarian cancer treatment. We, therefore, set out to explore the mechanism through which MSC-derived EVs delivered microRNA-424 (miR-424) to influence the development of ovarian cancer.
METHODS: Bioinformatics analyses were first performed to screen ovarian cancer-related differentially expressed genes and to predict regulatory miRNAs. Then, dual-luciferase reporter gene assay was carried out to verify the relationship between miR-424 and MYB. Subsequently, the characterized MSCs and isolated EVs were co-cultured with ovarian cancer cells, followed by determination of the expression patterns of miR-424, MYB, vascular endothelial growth factor (VEGF), and VEGF receptor (VEGFR), respectively. In addition, the effects of EVs-delivered miR-424 on the proliferation, migration, invasion and tube formation of ovarian cancer cells were assessed using gain- and loss-of-function approaches. Lastly, tumor xenograft was induced in nude mice to illustrate the influence of EVs-loaded miR-424 on ovarian cancer in vivo.
RESULTS: Our data exhibited that MYB was highly-expressed and miR-424 was poorly-expressed in ovarian cancer. More importantly, MYB was identified as a target gene of miR-424. Additionally, the transfer of miR-424 by MSC-derived EVs was found to repress the proliferation, migration, and invasion of ovarian cancer cells, with a reduction in the expressions of VEGF and VEGFR. Furthermore, MSC-derived EVs over-expressing miR-424 could inhibit the proliferation, migration, and tube formation of human umbilical vein endothelial cells, and also suppressed tumorigenesis and angiogenesis of ovarian tumors in vivo.
CONCLUSION: Collectively, our findings indicate that MSC-derived EVs transfer miR-424 to down-regulate MYB, which ultimately led to the inhibition of the tumorigenesis and angiogenesis of ovarian cancer. Hence, this study offers a potential prognostic marker and a therapeutic target for ovarian cancer.

Entities:  

Keywords:  Angiogenesis; Extracellular vesicle; Human umbilical vein endothelial cell; MYB; Mesenchymal stem cell; Ovarian cancer; VEGF; microRNA-424

Mesh:

Substances:

Year:  2021        PMID: 33407591      PMCID: PMC7786507          DOI: 10.1186/s12967-020-02652-x

Source DB:  PubMed          Journal:  J Transl Med        ISSN: 1479-5876            Impact factor:   5.531


  39 in total

1.  Exosomal RNA as biomarkers and the therapeutic potential of exosome vectors.

Authors:  Cecilia Lässer
Journal:  Expert Opin Biol Ther       Date:  2012-04-16       Impact factor: 4.388

2.  Methylation-mediated repression of MiR-424/503 cluster promotes proliferation and migration of ovarian cancer cells through targeting the hub gene KIF23.

Authors:  Tong Li; Yimin Li; Yaqi Gan; Ruotong Tian; Qihan Wu; Guang Shu; Gang Yin
Journal:  Cell Cycle       Date:  2019-06-09       Impact factor: 4.534

Review 3.  Ovarian cancer.

Authors:  Kathleen R Cho; Ie-Ming Shih
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

Review 4.  Ovarian cancer.

Authors:  Ursula A Matulonis; Anil K Sood; Lesley Fallowfield; Brooke E Howitt; Jalid Sehouli; Beth Y Karlan
Journal:  Nat Rev Dis Primers       Date:  2016-08-25       Impact factor: 52.329

5.  NbPHAN, a MYB transcriptional factor, regulates leaf development and affects drought tolerance in Nicotiana benthamiana.

Authors:  Changjun Huang; Gaojie Hu; Fangfang Li; Yunqin Li; Jianxiang Wu; Xueping Zhou
Journal:  Physiol Plant       Date:  2013-03-15       Impact factor: 4.500

6.  Parallel Regulation of von Hippel-Lindau Disease by pVHL-Mediated Degradation of B-Myb and Hypoxia-Inducible Factor α.

Authors:  Fumihiko Okumura; Keiji Uematsu; Stuart D Byrne; Mie Hirano; Akiko Joo-Okumura; Akihiko Nishikimi; Taro Shuin; Yoshinori Fukui; Kunio Nakatsukasa; Takumi Kamura
Journal:  Mol Cell Biol       Date:  2016-05-31       Impact factor: 4.272

7.  Down-regulation of mir-424 contributes to the abnormal angiogenesis via MEK1 and cyclin E1 in senile hemangioma: its implications to therapy.

Authors:  Taiji Nakashima; Masatoshi Jinnin; Tomomi Etoh; Satoshi Fukushima; Shinichi Masuguchi; Keishi Maruo; Yuji Inoue; Tsuyoshi Ishihara; Hironobu Ihn
Journal:  PLoS One       Date:  2010-12-14       Impact factor: 3.240

8.  Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness.

Authors:  Sandra Muñoz-Galván; Blanca Felipe-Abrio; Eva M Verdugo-Sivianes; Marco Perez; Manuel P Jiménez-García; Elisa Suarez-Martinez; Purificacion Estevez-Garcia; Amancio Carnero
Journal:  Mol Cancer       Date:  2020-01-11       Impact factor: 27.401

9.  LncRNA BLACAT1 Is Upregulated in Cervical Squamous Cell Carcinoma (CSCC) and Predicts Poor Survival.

Authors:  Hailing Cheng; Jun Tian; Chen Wang; Lu Ren; Ning Wang
Journal:  Reprod Sci       Date:  2020-01-06       Impact factor: 3.060

10.  Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer.

Authors:  Pinar Kanlikilicer; Recep Bayraktar; Merve Denizli; Mohammed H Rashed; Cristina Ivan; Burcu Aslan; Rahul Mitra; Kubra Karagoz; Emine Bayraktar; Xinna Zhang; Cristian Rodriguez-Aguayo; Amr Ahmed El-Arabey; Nermin Kahraman; Seyda Baydogan; Ozgur Ozkayar; Michael L Gatza; Bulent Ozpolat; George A Calin; Anil K Sood; Gabriel Lopez-Berestein
Journal:  EBioMedicine       Date:  2018-11-25       Impact factor: 8.143

View more
  9 in total

1.  miR-18a-5p derived from mesenchymal stem cells-extracellular vesicles inhibits ovarian cancer cell proliferation, migration, invasion, and chemotherapy resistance.

Authors:  Xiaoying Wang; Lili Jiang; Qifang Liu
Journal:  J Transl Med       Date:  2022-06-07       Impact factor: 8.440

Review 2.  Intricate crosstalk between MYB and noncoding RNAs in cancer.

Authors:  Dingyu Hu; Wenjun Shao; Li Liu; Yanyan Wang; Shunling Yuan; Zhaoping Liu; Jing Liu; Ji Zhang
Journal:  Cancer Cell Int       Date:  2021-12-07       Impact factor: 5.722

3.  Culture Condition of Bone Marrow Stromal Cells Affects Quantity and Quality of the Extracellular Vesicles.

Authors:  Amanda L Scheiber; Cierra A Clark; Takashi Kaito; Masahiro Iwamoto; Edwin M Horwitz; Yuka Imamura Kawasawa; Satoru Otsuru
Journal:  Int J Mol Sci       Date:  2022-01-18       Impact factor: 6.208

Review 4.  Mesenchymal stem cell-derived exosomes as new tools for delivery of miRNAs in the treatment of cancer.

Authors:  Aysegul Dalmizrak; Ozlem Dalmizrak
Journal:  Front Bioeng Biotechnol       Date:  2022-09-26

Review 5.  Roles of Mesenchymal Stem Cell-Derived Exosomes in Cancer Development and Targeted Therapy.

Authors:  Zixuan Sun; Jiaxin Zhang; Jiali Li; Mi Li; Jing Ge; Peipei Wu; Benshuai You; Hui Qian
Journal:  Stem Cells Int       Date:  2021-07-10       Impact factor: 5.443

Review 6.  Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer.

Authors:  Maritza P Garrido; Allison N Fredes; Lorena Lobos-González; Manuel Valenzuela-Valderrama; Daniela B Vera; Carmen Romero
Journal:  Biomedicines       Date:  2021-12-31

Review 7.  Anti-Cancer Role and Therapeutic Potential of Extracellular Vesicles.

Authors:  Naoomi Tominaga
Journal:  Cancers (Basel)       Date:  2021-12-15       Impact factor: 6.639

8.  Systematic analysis of the relationship between ovarian cancer prognosis and alternative splicing.

Authors:  Di Zhang; Dan Zou; Yue Deng; Lihua Yang
Journal:  J Ovarian Res       Date:  2021-09-15       Impact factor: 4.234

Review 9.  Cancer Angiogenesis and Opportunity of Influence on Tumor by Changing Vascularization.

Authors:  Igor Maiborodin; Alfija Mansurova; Alexander Chernyavskiy; Alexander Romanov; Vladimir Voitcitctkii; Anna Kedrova; Alexander Tarkhov; Alena Chernyshova; Sergey Krasil'nikov
Journal:  J Pers Med       Date:  2022-02-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.